LLY

1,059.93

+1.47%↑

JNJ

205.53

+1.23%↑

ABBV

236.05

+2.86%↑

UNH

321.42

+2.57%↑

AZN

91.12

+2.47%↑

LLY

1,059.93

+1.47%↑

JNJ

205.53

+1.23%↑

ABBV

236.05

+2.86%↑

UNH

321.42

+2.57%↑

AZN

91.12

+2.47%↑

LLY

1,059.93

+1.47%↑

JNJ

205.53

+1.23%↑

ABBV

236.05

+2.86%↑

UNH

321.42

+2.57%↑

AZN

91.12

+2.47%↑

LLY

1,059.93

+1.47%↑

JNJ

205.53

+1.23%↑

ABBV

236.05

+2.86%↑

UNH

321.42

+2.57%↑

AZN

91.12

+2.47%↑

LLY

1,059.93

+1.47%↑

JNJ

205.53

+1.23%↑

ABBV

236.05

+2.86%↑

UNH

321.42

+2.57%↑

AZN

91.12

+2.47%↑

Kodu・Aktsiate loetelu・Lexicon Pharmaceuticals Inc

Lexicon Pharmaceuticals Inc

Avatud

SektorTervishoid

1.33 -3.62

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

1.28

Max

1.37

Põhinäitajad
By Trading Economics
Sissetulek	-16M -13M
Müük	-15M 14M
Aktsiakasum	-0.04
Kasumimarginaal	-90.037
Töötajad	103
EBITDA	-16M -10M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+173.79% upside

Turustatistika
By TradingEconomics
Turukapital	36M 531M
Eelmine avamishind	4.95
Eelmine sulgemishind	1.33

Uudiste sentiment

By Acuity

57%

43%

330 / 374 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Bearish Evidence

0.6863 / 0.72 Toetus ja vastupanu

Lexicon Pharmaceuticals Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

20. nov 2025, 23:07 UTC

Market Talk

Evidence Of Broad Australian Economic Upswing Mounts -- Market Talk

20. nov 2025, 22:22 UTC

Market Talk

Auckland Airport Has Edge Over Transurban In Infrastructure Stocks -- Market Talk

20. nov 2025, 22:08 UTC

Market Talk

Revenues of Texas Battery Projects Drop Sharply -- Market Talk

20. nov 2025, 21:57 UTC

Tulu

Walmart Reports Strong Sales Growth, Raises Outlook -- 5th Update

20. nov 2025, 21:50 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Tech, Media & Telecom Roundup: Market Talk

20. nov 2025, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

20. nov 2025, 21:50 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Health Care Roundup: Market Talk

20. nov 2025, 21:50 UTC

Market Talk

Tulu

Financial Services Roundup: Market Talk

20. nov 2025, 21:31 UTC

Tulu

Nvidia's Strong Results Show AI Fears Are Premature -- Update

20. nov 2025, 21:23 UTC

Tulu

Omandamised, ülevõtmised, äriostud

These Stocks Moved the Most Today: Nvidia, Exact Sciences, Walmart, AMD, Alphabet, Palo Alto Networks, and More -- Barrons.com

20. nov 2025, 21:07 UTC

Tulu

Intuit Earnings Beat Estimates as Company Leans Into AI Strategy -- Barrons.com

20. nov 2025, 21:06 UTC

Tulu

Webull 3Q Rev $156.9M >BULL

20. nov 2025, 21:06 UTC

Tulu

Webull 3Q EPS 7c >BULL

20. nov 2025, 21:05 UTC

Tulu

Intuit 1Q Sales Jump, CFO Cites AI Demand From Mid-Sized Businesses -- Interview

20. nov 2025, 21:04 UTC

Tulu

Mid-Sized Businesses Want to Automate Tasks With AI, Intuit CFO Says >INTU

20. nov 2025, 21:04 UTC

Tulu

Intuit's AI Offerings Attracted More Mid-Sized Businesses in 1Q, CFO Says >INTU

20. nov 2025, 21:04 UTC

Tulu

Intuit Earnings Beat Estimates as Company Leans Into AI Strategy -- Barrons.com

20. nov 2025, 21:00 UTC

Tulu

Intuit Sees 2Q Rev $4.52B-$4.55B >INTU

20. nov 2025, 21:00 UTC

Tulu

Intuit Sees FY26 GAAP Operating Income $5.78B to $5.86B

20. nov 2025, 21:00 UTC

Tulu

Intuit Sees 2Q Adj EPS $3.63-Adj EPS $3.68 >INTU

20. nov 2025, 21:00 UTC

Tulu

Intuit Expects FY26 Global Business Solutions Rev Growth of 15.5% to 16.5%, Excluding Mailchimp

20. nov 2025, 21:00 UTC

Tulu

Intuit Expects FY26 Consumer Rev Growth of 8% to 9%

20. nov 2025, 21:00 UTC

Tulu

Intuit Expects FY26 Global Business Solutions Rev Growth of 14% to 15%

20. nov 2025, 21:00 UTC

Tulu

Intuit Backs FY26 Rev $21B-$21.19B >INTU

20. nov 2025, 21:00 UTC

Tulu

Intuit Backs FY26 Adj EPS $22.98-Adj EPS $23.18 >INTU

20. nov 2025, 21:00 UTC

Tulu

Intuit 1Q Consumer Rev $894M

20. nov 2025, 21:00 UTC

Tulu

Intuit Sees 2Q EPS $1.76-EPS $1.81 >INTU

20. nov 2025, 21:00 UTC

Tulu

Intuit Backs FY26 Guidance

20. nov 2025, 21:00 UTC

Tulu

Intuit Backs FY26 EPS $15.49-EPS $15.69 >INTU

20. nov 2025, 21:00 UTC

Tulu

Intuit 1Q Global Business Solutions Rev $3B

Võrdlus sarnastega

Hinnamuutus

Lexicon Pharmaceuticals Inc Prognoos

Hinnasiht

By TipRanks

173.79% tõus

12 kuu keskmine prognoos

Keskmine 3.97 USD 173.79%

Kõrge 6 USD

Madal 1.9 USD

Põhineb 3 Wall Streeti analüütiku instrumendi Lexicon Pharmaceuticals Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

3 ratings

Osta

Hoia

Müü

Põhineb 3 analüütiku instrumendi Lexicon Pharmaceuticals Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

0.6863 / 0.72Toetus ja vastupanu

Recent bearish events outweigh bullish events.

All events are bullish.

There is one bearish event.

Sentiment

By Acuity

330 / 374 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Lexicon Pharmaceuticals Inc

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.